Provides nucleic stabilization and purification kits for primary sample materials. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
The market pays 20.6× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 64% of them.
Analysts' average target sits 1% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $2.64 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 2% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, QGEN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: QGEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.